Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.35 | 0.72 | 0.67 |
| Expenses | 0.01 | 0.00 | 0.00 | 0.00 | 0.07 | 0.02 | 0.04 | 0.04 | 0.23 | 0.47 | 0.78 | 0.79 |
| Operating Profit | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| OPM % | -15.00% | -34.29% | -8.33% | -17.91% | ||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||
| Net Profit | -0.01 | 0.00 | 0.00 | 0.00 | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| EPS in Rs | -0.01 | 0.00 | 0.00 | 0.00 | -0.06 | -0.02 | -0.03 | -0.03 | -0.02 | -0.10 | -0.05 | -0.10 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 | 0.00 | 1.27 | 1.94 |
| Expenses | 0.03 | 0.12 | 0.05 | 0.10 | 0.15 | 0.06 | 0.04 | 0.00 | 0.02 | 0.14 | 1.52 | 2.27 |
| Operating Profit | 0.00 | -0.06 | -0.05 | -0.10 | -0.15 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.25 | -0.33 |
| OPM % | 0.00% | -100.00% | -19.69% | -17.01% | ||||||||
| Other Income | 0.00 | 0.00 | 0.03 | 0.02 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.25 | -0.33 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Net Profit | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.25 | -0.33 |
| EPS in Rs | 0.00 | -0.05 | -0.02 | -0.07 | 0.00 | -0.05 | -0.07 | 0.00 | -0.02 | -0.12 | -0.21 | -0.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 36% | % | % | % | ||
| Compounded Profit Growth | % | % | % | -94% | ||
| Stock Price CAGR | 25% | 64% | % | % | ||
| Return on Equity | % | % | % | % |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | -2.33 | -2.45 | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3.00 | -3.00 | -3.21 | -3.35 | -4.24 |
| Borrowings | 0.00 | 0.01 | 0.01 | 0.17 | 0.21 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.25 | 1.47 |
| Other Liabilities | 0.09 | 0.09 | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.17 | 0.12 | 0.94 |
| Total Liabilities | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 1.18 |
| Fixed Assets | 0.27 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.45 | 0.46 | 0.44 | 0.59 | 0.60 | 0.08 | 0.04 | -0.01 | 0.00 | 0.01 | 0.03 | 1.18 |
| Total Assets | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 1.18 |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| Cash from Investing Activity | 0.01 | 0.02 | 0.07 | -0.07 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activity | 0.00 | 0.01 | 0.00 | 0.16 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.21 | 0.58 |
| Net Cash Flow | 0.00 | 0.00 | 0.03 | 0.10 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.02 | -0.01 |
| Free Cash Flow | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| CFO/OP | -33% | 67% | -20% | 20% | 7% | 17% | 50% | 50% | 136% | 236% |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | 172.44 | |||||||
| Inventory Days | 0.00 | 0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | 172.44 | |||||||
| Working Capital Days | 1,460.00 | 4,015.00 | 1,460.00 | -1,642.50 | -359.25 | |||||||
| ROCE % | 4.51% | 0.00% | -11.11% | -3.45% | -12.70% | -50.00% | -160.00% | 0.00% | -333.33% |
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 77.00% |
| Public | 58.70% | 58.71% | 58.71% | 58.70% | 58.70% | 58.70% | 58.71% | 58.72% | 58.72% | 58.72% | 58.70% | 23.00% |
| No. of Shareholders | 2,440 | 2,432 | 2,431 | 2,445 | 2,430 | 2,427 | 2,442 | 2,427 | 504 | 2,475 | 2,465 | 2,457 |
Fundamentals
Market Cap₹ 53.3 Cr.
Current Price₹ 47.9
Book Value₹ -1.02
ROCE-333 %
ROE%
Dividend Yield0.00 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)-94%
Standalone figures.
Valuation
Market capRs 30 Cr
Enterprise valueRs 32 Cr
Price to book-24.44x
Price to sales15.49x
EV / sales16.24x
Earnings yield-1.10%
P/B, 3-year average-13.09x
P/B, 5-year average51.72x
Profitability
Operating margin (excl. other income)-19.68%
Operating margin (incl. other income)-19.68%
EBITDA margin-17.01%
Pre-tax margin-17.01%
Net profit margin-17.01%
Net margin, latest quarter-17.91%
ROE31.85%
ROCE-333.33%
ROA-41.32%
ROE, 3-year average34.92%
ROCE, 3-year average-333.33%
ROA, 3-year average-253.46%
ROE, 5-year average-21.05%
ROCE, 5-year average-181.11%
ROA, 5-year average-164.13%
ROIC (approx.)-150.00%
Growth
Sales growth QoQ-6.94%
Per share
EPS (TTM)Rs -0.55
EPS (latest year)Rs -0.41
EPS (latest quarter)Rs -0.20
EPS, 3-year averageRs -0.23
EPS, 5-year averageRs -0.18
Book value per shareRs -2.04
Sales per shareRs 3.22
Cash flow per shareRs -0.98
Free cash flow per shareRs -0.98
Efficiency
Asset turnover1.08x
Debtor days172 days
Debtors turnover2.12x
Cash conversion cycle172 days
Working capital days-359 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 0 Cr
Net debtRs 1 Cr
Debt to equity-1.20x
Owners' fund to total sources-104.24%
Debt to assets124.58%
Cash flow
Cash from Operating Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -1 Cr
FCFE (approx.: FCF + change in debt)Rs 1 Cr
Statement figures
Net sales (TTM)Rs 2 Cr
Net sales (latest year)Rs 1 Cr
Sales (latest quarter)Rs 1 Cr
Operating profit excl. other income (latest year)Rs -0 Cr
Operating profit (latest quarter)Rs -0 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -0 Cr
Profit before tax (TTM)Rs -0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -0 Cr
Cost of goods sold (latest year)Rs 1 Cr
Total expenditure (latest year)Rs 2 Cr
Total income (latest year)Rs 1 Cr
Share capitalRs 3 Cr
ReservesRs -4 Cr
Shareholders' fundsRs -1 Cr
Total assetsRs 1 Cr
ReceivablesRs 1 Cr
Other liabilitiesRs 1 Cr
Shares outstanding (crore)0.60
Ownership
Promoter holding77.00% (+35.70 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 526075 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -2.1% | -2.8% | +0.7 pts |
| 1 month | +4.2% | -6.8% | +11.0 pts |
| 3 months | +35.8% | -7.6% | +43.4 pts |
| 3 years | +1008.0% | +14.2% | +993.8 pts |
| 5 years | +1092.8% | +27.9% | +1064.9 pts |
Red flags
F-score 3 of 6| serious | Negative equity Shareholders' equity is negative |
| explain | High accruals Profit exceeded operating cash by 29% of total assets in 2026 |
| explain | Debt up, profit down Borrowings up 488% while net profit fell in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹1 Cr.
Net loss ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Rekvina Labs Ltd?
Rekvina Labs Ltd (526075) has a market capitalisation of Rs 53.3 Cr. at the 2026-10-01 close.
What were Rekvina Labs Ltd's latest quarterly results?
In the Jun 2026 quarter, Rekvina Labs Ltd sales was Rs 1 Cr with a net loss of Rs 0 Cr.